Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Breast 3Gynecologic 2Gastrointestinal 2Genitourinary 1

Conditions

Breast Neoplasms 9Colorectal Neoplasms 6Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 20Gemcitabine 10Nivolumab 8Irinotecan 8atezolizumab 7durvalumab 6Docetaxel 6sargramostim 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5aldesleukin 4Psychiatric Rehabilitation 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cisplatin 4tislelizumab 3spartalizumab 3avelumab 3Topotecan 3Therapeutics 3Polymerase Chain Reaction 3Carboplatin 3Bevacizumab 3tremelimumab 2talazoparib 2surufatinib 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Fulvestrant × Gastrointestinal × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04247126 2023-10-27

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Syros Pharmaceuticals

Phase 1 Completed
105 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡